Pancreatic Cancer Research

ResearcherTokai UniversityActive in the last 2 years

Shutaro Hori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9213-0758; OpenAlex author ID A5020594980. Sources: OpenAlex.

Their work

Papers
20
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 5 papers · 2025: 2 papers · 2026: 3 papers

Papers 20

  1. Impact of Sarcopenia During Induction Treatment in Patients With Unresectable Locally Advanced Pancreatic Cancer. Co-author DOI 10.1002/ags3.70078↗
  2. Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02343-2↗
  3. Postoperative risk stratification after upfront surgery for resectable pancreatic ductal adenocarcinoma in the S-1 adjuvant era. Co-author DOI 10.1016/j.pan.2026.05.008↗
  4. Clinical Impact of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Study. Co-author DOI 10.1245/s10434-024-16851-z↗
  5. Pancreatic Cancer Mimicking Relapse of Autoimmune Pancreatitis: Case Reports. Co-author DOI 10.70352/scrj.cr.25-0076↗
  6. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-72569-8↗
  7. Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera. Co-author DOI 10.1111/cas.16341↗
  8. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. Co-author DOI 10.1186/s12957-024-03609-w↗
  9. Efficacy and safety of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4671932/v1↗
  10. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Co-author DOI 10.3892/ol.2024.14272↗
  11. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report. Co-author DOI 10.1097/md.0000000000035856↗
  12. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen. Co-author DOI 10.1158/1078-0432.ccr-20-2298↗
  13. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. Co-author DOI 10.3748/wjg.v27.i3.294↗
  14. Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant thera… Co-author DOI 10.1002/cam4.3044↗
  15. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Co-author DOI 10.1111/cas.14425↗
  16. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Co-author DOI 10.1111/cas.14514↗
  17. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  18. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline rese… Co-author DOI 10.1186/s12957-019-1687-4↗
  19. Reliable evaluation of tumor-infiltrating lymphocytes in pancreatic cancer tissue biopsies. Co-author DOI 10.18632/oncotarget.26646↗
  20. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-016-2026-6↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Kitago · 17 shared papers, 2019–2026 · strength 3.01
  2. Yuta Abe · 16 shared papers, 2019–2026 · strength 2.88
  3. Yutaka Nakano · 14 shared papers, 2019–2026 · strength 2.57
  4. Masayuki Tanaka · 11 shared papers, 2021–2026 · strength 2.28
  5. Yohei Masugi · 13 shared papers, 2019–2026 · strength 2.02
  6. Yuko Kitagawa · 12 shared papers, 2016–2026 · strength 1.81
  7. Gaku Shimane · 5 shared papers, 2024–2026 · strength 1.05
  8. Sho Uemura · 4 shared papers, 2024–2026 · strength 0.95
  9. Yuko Kitagawa · 4 shared papers, 2024–2025 · strength 0.83
  10. Yutaka Endo · 4 shared papers, 2019–2024 · strength 0.45
  11. Hiroshi Nishihara · 2 shared papers, 2024 · strength 0.37
  12. Eisuke Iwasaki · 2 shared papers, 2021–2025 · strength 0.34
  13. Hideaki Kojima · 2 shared papers, 2021–2025 · strength 0.34
  14. Michiie Sakamoto · 3 shared papers, 2020–2021 · strength 0.30
  15. Satoru Matsuda · 1 shared paper, 2026 · strength 0.30
  16. Kohei Mishima · 1 shared paper, 2026 · strength 0.30
  17. Koichi Aiura · 2 shared papers, 2019–2024 · strength 0.27
  18. Yoshinori Ino · 3 shared papers, 2016–2020 · strength 0.27
  19. Kazuaki Shimada · 3 shared papers, 2016–2020 · strength 0.27
  20. Nobuyoshi Hiraoka · 3 shared papers, 2016–2020 · strength 0.27
  21. Yosuke Uematsu · 1 shared paper, 2026 · strength 0.26
  22. Yasuaki Kabe · 2 shared papers, 2020–2024 · strength 0.26
  23. Takahiro Yokose · 3 shared papers, 2020 · strength 0.25
  24. Satoshi Nara · 3 shared papers, 2016–2020 · strength 0.23
  25. Yasunori Sato · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.